title: Severe Ulcerative Esophagitis Induced by Crizotinib Therapy.
abstract: Crizotinib is an oral tyrosine-kinase inhibitor that inhibits anaplastic lymphoma kinase (ALK) in gene-rearranged non-small cell lung cancer (NSCLC). In 2011, the Food and Drug Administration approved crizotinib for treatment of locally advanced or metastatic ALK-positive NSCLC. The crizotinib adverse events profile included esophageal disorders in 11% of patients treated during trial phases I, II, and III, but none of them had severe events. We describe the development of severe ulcerative esophagitis secondary to crizotinib therapy and the re-introduction of therapy at a lower dose without recurrence of esophageal symptoms.
authors.affiliation: Internal Medicine Department, McLeod Regional Medical Center, Florence, SC.
authors.forename: Ala' A Abdel
authors.initials: AA
authors.lastname: Jalil
authors.affiliation: Pharmacy Department, McLeod Regional Medical Center, Florence, SC.
authors.forename: Jamie
authors.initials: J
authors.lastname: Craig
authors.affiliation: Division of Hematology/Oncology, McLeod Regional Medical Center, Florence, SC.
authors.forename: Rajesh
authors.initials: R
authors.lastname: Bajaj
authors.affiliation: Division of Gastroenterology and Hepatology, McLeod Regional Medical Center, Florence, SC.
authors.forename: Timothy
authors.initials: T
authors.lastname: Spurling